Australia's most trusted
source of pharma news
Saturday, 02 August 2025
">
Posted 30 July 2025 PM
MSD is the latest Big Pharma to announce sweeping cost cuts that will involve job losses plus a downsize of the company's real estate footprint in a bid to save US$3 billion by 2027.
The announcement was made during the company's second quarter results which showed sales were down two per cent on the same time last year from US$16.1 billion to $15.8 billion.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.